Oncology MoA Animation
We created this mechanism of action (MoA) animation for Novartis for their oncology product, TABRECTA™. TABRECTA™ (capmatinib) tablets are indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
This medical animation, based on in vitro/in vivo studies, uses scientific storytelling to explain the action of TABRECTA™ tablets. The animation uses eye-catching visuals to captivate and engage the viewer. The animation explains METex14 in NSCLC, the role of MET in cell signaling, and capmatinib’s MoA.
TABRECTA™ is a kinase inhibitor, operating by blocking a key enzyme that results in helping to stop the tumor cells from growing. This treatment is intended for patients who have NSCLC that has spread to other parts of the body or cannot be removed by surgery, and whose tumors have an abnormal mesenchymal-epithelial transition (MET) gene.
This animation is featured online as part of the Novartis website intended for Healthcare professionals (HCPs).
The animation is hosted on the TABRECTA™ product page for HCPs to learn more about the product, where they can explore related product resources such as the efficacy, safety profile, product dosing, and administration.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen